Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

UVA Tracking #
Principal Investigator
Emily Ayers
Contact Phone
Official Trial Title
A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell l
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for adults ages 75 and over who have newly diagnosed Diffuse Large B cell Lymphoma (DLBCL). This study will look at the effects of the combination of two drugs: an investigational chemotherapy drug + standard drug therapy. The goal is to see if this approach is better than standard of care.

The total length of your participation in unknown. Each cycle is 21 days and the number of cycles you complete is up to 6 cycles. Once you are off treatment, you will need to come in for 3 more visits. The study team will follow-up with you for up to 5 years after treatment. Any procedures being done above and beyond standard of care will be provided at no cost to you or your insurance.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04799275